These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 30222436)

  • 1. How the Critical Path Initiative Addresses CDER's Regulatory Science Needs: Some Illustrative Examples.
    Geanacopoulos M; Barratt R
    Ther Innov Regul Sci; 2015 Jul; 49(4):466-472. PubMed ID: 30222436
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An FDA Analysis of Formal Dispute Resolution in the Center for Drug Evaluation and Research: 2003 Through 2014.
    Sharma K; Harrington A; Worrell S; Bertha A
    Ther Innov Regul Sci; 2016 Nov; 50(6):697-704. PubMed ID: 30231744
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Paving the critical path of drug development: the CDER perspective.
    Woodcock J
    Nat Rev Drug Discov; 2014 Nov; 13(11):783-4. PubMed ID: 25359359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lessons from CDER's Quality Management Maturity Pilot Programs.
    Maguire J; Fisher A; Harouaka D; Rakala N; Lundi C; Yambot M; Viehmann A; Stiber N; Gonzalez K; Canida L; Buhse L; Kopcha M
    AAPS J; 2023 Jan; 25(1):14. PubMed ID: 36627496
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blood safety: Opportunities and challenges addressed through Critical Path research at FDA.
    Atreya CD; Epstein JS
    Drug Discov Today Technol; 2007; 4(2):51-4. PubMed ID: 24980841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Translating New Science Into the Drug Review Process: The US FDA's Division of Applied Regulatory Science.
    Rouse R; Kruhlak N; Weaver J; Burkhart K; Patel V; Strauss DG
    Ther Innov Regul Sci; 2018 Mar; 52(2):244-255. PubMed ID: 29568713
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advancing pharmaceutical quality: An overview of science and research in the U.S. FDA's Office of Pharmaceutical Quality.
    Fisher AC; Lee SL; Harris DP; Buhse L; Kozlowski S; Yu L; Kopcha M; Woodcock J
    Int J Pharm; 2016 Dec; 515(1-2):390-402. PubMed ID: 27773853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interview with Janet Woodcock: progress on the FDA's critical path initiative.
    Woodcock J
    Biomark Med; 2009 Dec; 3(6):671-3. PubMed ID: 20477704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Building a roadmap to biomarker qualification: challenges and opportunities.
    Amur SG; Sanyal S; Chakravarty AG; Noone MH; Kaiser J; McCune S; Buckman-Garner SY
    Biomark Med; 2015; 9(11):1095-105. PubMed ID: 26526897
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expanded Access of Investigational Drugs: The Experience of the Center of Drug Evaluation and Research Over a 10-Year Period.
    Jarow JP; Lemery S; Bugin K; Khozin S; Moscicki R
    Ther Innov Regul Sci; 2016 Nov; 50(6):705-709. PubMed ID: 27917324
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An FDA/CDER perspective on nonclinical testing strategies: Classical toxicology approaches and new approach methodologies (NAMs).
    Avila AM; Bebenek I; Bonzo JA; Bourcier T; Davis Bruno KL; Carlson DB; Dubinion J; Elayan I; Harrouk W; Lee SL; Mendrick DL; Merrill JC; Peretz J; Place E; Saulnier M; Wange RL; Yao J; Zhao D; Brown PC
    Regul Toxicol Pharmacol; 2020 Jul; 114():104662. PubMed ID: 32325112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biomedical applications of tissue engineering technology: regulatory issues.
    Hellman KB
    Tissue Eng; 1995; 1(2):203-10. PubMed ID: 19877928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Revocation of Office of Generic Drug's interim policy statement on inactive ingredients. Food and Drug Administration, HHS. Notice.
    Fed Regist; 1999 Apr; 64(83):23340-1. PubMed ID: 10558498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protecting the public's health through the application integrity policy.
    Katz PR
    Food Drug Law J; 2010; 65(3):539-43, iii. PubMed ID: 24479240
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FDA's expanding postmarket authority to monitor and publicize food and consumer health product risks: the need for procedural safeguards to reduce "transparency" policy harms in the post-9/11 regulatory environment.
    Roller ST; Pippins RR; Ngai JW
    Food Drug Law J; 2009; 64(3):577-98. PubMed ID: 19999646
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An integrated bioinformatics infrastructure essential for advancing pharmacogenomics and personalized medicine in the context of the FDA's Critical Path Initiative.
    Tong W; Harris SC; Fang H; Shi L; Perkins R; Goodsaid F; Frueh FW
    Drug Discov Today Technol; 2007; 4(1):3-8. PubMed ID: 24980713
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Center for Drug Evaluation and Research Perspective on Quality in Clinical Trials.
    Shapley S; O'Shaughnessy J; Woodcock J
    Ther Innov Regul Sci; 2017 Jul; 51(4):416-418. PubMed ID: 30227045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluating the Use of KIM-1 in Drug Development and Research Following FDA Qualification.
    Chen R; Sanyal S; Thompson A; Ix JH; Haskins K; Muldowney L; Amur S
    Clin Pharmacol Ther; 2018 Dec; 104(6):1175-1181. PubMed ID: 29761868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advancing global health through regulatory science research: summary of the Global Summit on Regulatory Science Research and Innovation.
    Slikker W; Miller MA; Lou Valdez M; Hamburg MA
    Regul Toxicol Pharmacol; 2012 Apr; 62(3):471-3. PubMed ID: 22342950
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.